Skip to main content
Myles Wolf, MD, Nephrology, Durham, NC

Myles Selig Wolf MD MMSc


Charles Johnson, MD Professor of Medicine and Chief of Division of Nephrology, Duke University School of Medicine

Join to View Full Profile
  • 2 Genome CourtRoom 1009Durham, NC 27710

  • Phone+1 919-613-5914

Dr. Wolf is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General HospitalFellowship, Nephrology, 1999 - 2002
  • Mass General Brigham/Massachusetts General Hospital
    Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1996 - 1999
  • State University of New York Downstate Medical Center College of Medicine
    State University of New York Downstate Medical Center College of MedicineClass of 1996

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2024 - 2026
  • NC State Medical License
    NC State Medical License 2016 - 2025
  • IL State Medical License
    IL State Medical License 2013 - 2017
  • FL State Medical License
    FL State Medical License 2008 - 2014
  • MA State Medical License
    MA State Medical License 1998 - 2009
  • Nephrology
    American Board of Internal Medicine Nephrology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Diet and Acid in CKD: Where Do We Stand? 
    American Society of Nephrology Kidney Week 2019 - Washington, D.C. - 11/7/2019

Press Mentions

  • New Kidney Function Test Takes Race Out of the Equation
    New Kidney Function Test Takes Race Out of the EquationSeptember 23rd, 2021
  • Clinical Trial Sheds New Light on Potential Risk Associated with Intravenous Iron Treatment
    Clinical Trial Sheds New Light on Potential Risk Associated with Intravenous Iron TreatmentDecember 6th, 2018
  • Etelcalcetide Reduces PTH Levels in Moderate to Severe SHPT
    Etelcalcetide Reduces PTH Levels in Moderate to Severe SHPTJanuary 11th, 2017
  • Join now to see all

Grant Support

  • HiLo Competitive RenewalDUKE UNIVERSITY2018–2025

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: